Lower hepatotoxicity risk in Xelaglifam, a novel GPR40 agonist, compared to Fasiglifam for type 2 diabetes therapy.
Yoon J, Song H, Park JS, Kim JH, Jun Y, Gim SA, Hong C, An KM, Park JT, Lee JW, Yoon H, Kim YS, Kim SG.
Yoon J, et al. Among authors: kim sg.
Biomed Pharmacother. 2024 Nov 12;181:117674. doi: 10.1016/j.biopha.2024.117674. Online ahead of print.
Biomed Pharmacother. 2024.
PMID: 39536537
Free article.